Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
AC Immune SA
AC Immune SA
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
AC Immune strengthens management, appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover
Pharmaceutical
AC Immune SA appoints Dr Marie Kosco-Vilbois
Neurodegenerative Disease company has new Chief Scientific Officer
Pharmaceutical
New strategic partnership focuses on Alzheimers
Swiss AC Immune and Chinese WuXi Biologics sign agreement
Research & Development
AC Immune and Lilly announce licence and collaboration agreement
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases
Pharmaceutical
Landmark for AC Immune Alzheimer and Down Syndrome vaccines
The swiss clinical stage biopharmaceutical company has a broad pipeline focused on neurodegenerative diseases
Subscribe now